

# Antihyperglycemic Coverage by RAMQ

Class	Medication	\$/day at max dose	MONO if SU and MET NT or CI	+ MET if SU CI,NT or INEFF	+ SU if Met CI, NT or INEFF	IF CVD + A1c>7	+ MET if DPP4i INEFF, NT or CI and BMI > 30 and high A1c	If other SU NT or INEFF
Biguanides	Metformin (Glucophage)	0.18						
α-Glucosidase Inhibitors	Acarbose (Glucobay)	1.03						
DPP-4 Inhibitors	Alogliptin (Nesina)	2.10	EN167	EN148 (EN150 Kazano)	EN149			
	Linagliptin (Trajenta)	2.25	EN167	EN148 (EN150 Jentaduetto)				
	Saxagliptin (Onglyza)	2.30		EN148 (EN150 Komboglyze)	EN149			
	Sitagliptin (Januvia)	2.62	EN167	EN148 (EN150 Janumet et XR)				
SGLT2 Inhibitors	Canagliflozin (Invokana)	2.62	EN167	EN148	EN149			
	Dapagliflozin (Forxiga)	2.45		EN148 (EN199 Xigduo)	EN149			
	Empagliflozin (Jardiance)	2.62	EN167	EN148 (EN199 Synjardy)		EN179		
GLP-1R Agonists	Liraglutide (Victoza)	6.85					Form	
	Exenatide (Byetta)	2.49						
	Exenatide QW (Bydureon)	6.85						
	Dulaglutide (Trulicity)	6.85					Form	
	Semaglutide (Ozempic)	6.85						
Thiazolidinediones	Pioglitazone (Actos)	1.05	EN121	EN118	EN119			
	Rosiglitazone (Avandia)	2.87	EN121	EN118 (EN81 Avandamet)	EN119			
Insulin Secretagogues	Gliclazide (Diamicron)	0.50						
	Glimepiride (Amaryl)	0.77						EN23
	Glyburide (Diabeta)	0.23						
	Repaglinide (GlucoNorm)	0.84						

Green = on general list: no code or form required Orange = Médicament d'exception: code or form required

NT=Not tolerated INEFF=Inefficacious CI=Contraindicated SU=Sulfonylurea MET=Metformin Mono=Monotherapy Form=Médicament d'exception form required  
EN199 requires 3 month stability of each component x 3 months JF Yale october 2018